Misty Dawn Shields✓

Always incredible to catch up with my lifelong mentor, hero, and friend, Dr. John Minna. @iaslungcancer #sclc23 #lcsm #mentorship #lungcancerresearch

Incredibly honored to be a part of this important initiative with @LungCancerEu that highlights the current state of small cell lung cancer care and the challenges our @SclcSMASHERS face. These include limited or no involvement in treatment decision making, few being offered clinical trials, and major gaps in available support. Many patients access the internet for information that may be outdated or inaccurate for their own case. Dr. Google is simply not a good doctor. While we have seen such unprecedented progress in small cell lung cancer care, namely immunotherapy, T-cell engagers, lurbinectedin, and ADCs, breakthroughs in scientific advances only matter if people can actually reach them. #SCLC #LCSM @LungCancerEu @LUNGevity @myESMO @ASCO @MedicalEmanet @FDA @OncoAlert @oncodaily @OncLive @LungSummit @g_mountzios @LuisPaz_Ares @Alfdoc2 @peters_solange @StephenVLiu @pedrofsrocha @FordePatrick

Read the full report at 🔗:

RT @KolPulseAI: #ESMO26: 5 facts Pharma MSLs may forget to tell you — but KOLs have your back! Control-arm gaps, no crossover, and "only 9% of pts got Krazati" @dr_yakupergun @drshieldsmd @nlindenberg @LoiSher @ByMadeleineA @Genentech @AstraZeneca @Merck @AmgenOncology

Today, the Phase 3 results of DeLLphi-305 (@AmgenOncology @AstraZeneca) were presented by @sands_jacob at #ESMO26. DeLLphi-305 delivered an unprecedented OS improvement (21.1 vs 12.7 mo, HR 0.42) for patients receiving tarlatamab + durvalumab, compared to durvalumab alone, in 1L maintenance after chemoIO induction for ES-SCLC. Studies like these provide renewed hope. However, this data brings forth multiple concerns regarding international access to care, interpretation of contribution of parts, patient selection, and sequencing. 1️⃣ Equitable access to cross-over: at time of POD, only 12.2% of ITT population in the durvalumab arm (34/278) and 18.9% (34/179) of those who received subsequent anti-cancer therapies had access to tarlatamab. This speaks to the global need to expand access to this life-saving therapy, as DeLLphi-301 demonstrated this impact with accessibility promptly available here in the USA as early as May 2024. Yet, @SclcSMASHERS all over the world still do not have this option even at relapse. 2️⃣ Line of therapy: while attrition to 2L may be significant in some practices & highlights the need to maximize proactive support & early palliative care, is there clear evidence of synergy with ICI+DLL3 TCE to transform outcomes, or is the effect additive? Preclinical data suggested synergy with this combination approach. However, within subgroup analyses of those receiving tarlatamab in subsequent treatment, particularly in the USA, it appears there is signal of additivity, given the nullification of OS benefit with DLL3 TCE cross-over (in those receiving it as 2nd LOT). Outside of risk of attrition, what variables favor using tarlatamab in 1LM vs 2L? Is the NE biology still preserved? Is the function of the immune system equivalently preserved following <4 weeks post chemoIO with myelosuppression? 3️⃣ Patient selection: Stratification with effective predictive biomarkers are key to know who can avoid any intensification, as they may be a durable ICI responder to monotherapy ICI. Who can we avoid tarlatamab every 2 weeks indefinitely? Who should receive lurbi + atezo? Or durva + tarla? More translational SCLC based biomarkers, beyond DLL3, are clearly of high unmet need to guide strategies. 4️⃣ Sequencing: if we use tarlatamab+durvalumab in the 1LM, what’s next? At POD, what approved option remains? Lurbi remains approved in the 1LM, but not at relapse. I-DXd BLA was voluntarily withdrawn. Trials are key, but enrollment for most global studies is brisk, particularly in the USA where enrollment is ~20% or less of the total cohort. @SclcSMASHERS @LUNGevity @IASLC @ASCO @NCCN @LungCancerEu @lcrf_org @OncBrothers @OncoAlert @oncodaily @OncLive @lungoncdoc @RManochakian @LauraAlderMD @LaurenByersMD @Annechiangmd

RT @EddieSantosMD: Change of practice in ED-SCLC. Significantly improvement in OS based on the DeLLphi-305 study presented by Jacob Sands at 2026 ESMO. This is the new standard of care. Median OS 21.1 months!!!. Discussant, Stephen Liu emphasized: amazing OS, better safety profile in maintenance and we need global access to this therapy. @sands_jacob @StephenVLiu @ASCO @IASLC @StarlingOnc @edgardo_ny

RT @Tony_Calles: 📖 A new chapter in SCLC therapy has been written by @sands_jacob 💥 DeLLphi-305 sets a new standard of care in maintenance after induction chemo-io for patients with ES-SCLC #ESMO26 @myESMO

RT @Alfdoc2: 🔥 DeLLphi-305 shook the room at #ESMO26 and what a spectacular discussion by @StephenVLiu Outstanding data deserve an equally outstanding discussion, and Stephen delivered! 👏 💥 OS HR 0.42 , unprecedented impact in ES-SCLC! Key questions: CNS efficacy, long-term survival, predictive biomarkers and optimal treatment sequencing. Encouraging outpatient feasibility and improved monitoring requirements. And one crucial message: global access to this breakthrough treatment must become a priority. Spectacular science, spectacular discussion! A truly unforgettable ESMO Plenary! #ESMOAmbassadors #ESMO26 #DeLLphi305 #SCLC #LungCancer

RT @RManochakian: 🚨🔥@OncoAlert Hot Off The Press. Just presented @myESMO #ESMO26 by @sands_jacob the long-awaited #PracticeChanging results of: ⭐️ #DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ✅#ORR: 26.4 % vs 4.1% ✅ Safety Data: ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%)

RT @NEJM: Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: @myESMO

RT @g_mountzios: #ESMO26 Presidential 1: As Tarlatamab moves from the 2L to the 1L setting, it suddenly becomes taller 😄😄 Congrats @sands_jacob , we are here to celebrate with you for the dawn of a new era for our patients with #SCLC @myESMO @SclcSMASHERS @StephenVLiu

RT @g_mountzios: #ESMO26 Presidential 1 : #SCLC DeLLphi-305: Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC! #Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42. 80% of patients alive and 38% progression-free at 12 months The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨ @myESMO @SclcSMASHERS #ESMOAmbassadors

RT @RManochakian: 🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻

RT @ADesaiMD: #ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily

RT @OncLive: Is KRAS G12C following the EGFR playbook in NSCLC? Eric K. Singhi, MD, and Misty D. Shields, MD, PhD, on its path toward the neoadjuvant setting. Watch now on OncLive®: @lungoncdoc @MDAndersonNews @drshieldsmd @IUCancerCenter #NSCLC #LCSM

This event isn’t a lecture you sit through, but a dynamic conversation on the rapidly evolving lung cancer treatment landscape. With so many exciting trials presented this year at @ASCO, @IASLC #WCLC, and @myESMO, how should we implement these results into our practices to provide high-quality cutting edge care for our patients impacted by lung cancer? On November 11, I’m leading a State of the Science Summit® (#SOSS) on Lung Cancer supported by @OncLive with thoracic oncology experts Drs. Julian Marin-Acevedo @jmarinacevedo, Nasser Hanna @hannawants2ELCN, & DuyKhanh (Mimi) Ceppa @girlceppa built around open panel discussion: How we interpret emerging data and what these important updates mean for the patients we treat. The event is complimentary, includes dinner, drinks, and a raffle entry. The SOSS takes place at beautiful 🏨@HotelCarmichael, Autograph Collection in @cityofcarmelin. 🪑Seats are limited, so register today!

🔗:

RT @Latinamd: Thanks for the invitation @OncBrothers to discuss latest data on SCLC with the amazing @drshieldsmd @SclcSMASHERS @OncUpdates

⭐️Emerging therapies &amp; evolving strategies in #SCLC @OncBrothers 🗣️ w/ @drshieldsmd + @Latinamd ✅ Tarlatamab emerging as important 2L option ✅ #MAVERICK: MRI surveillance preferred over PCI 🗣️ ADCs may further expand options #lcsm #OncTwitter #HemOnc

RT @KolPulseAI: The top KOLs in Thoracic Oncology just met at #DClung26 Learn what data they discussed👉

RT @KolPulseAI: “The room went with NeoADAURA but great case made for both shows how each case is unique.” — @StephenVLiu on the #DCLung26 debate: NeoADAURA vs LAURA DC Lung 2026 page: 116 slides with text, 79 faculty, 70 trials. Posts by @drshieldsmd @Joshua_Reuss @Latinamd. 👉Follow what Thoracic Oncology KOLs are sharing with one another! Full page: